Methods and compositions for treating hypoglycemic disorders

• US 9,616,108 B2
• Filed: 04/10/2008
• Issued: 04/11/2017
• Est. Priority Date: 01/08/2007
• Status: Active Grant

• Current Assignee: Children's Hospital of Philadelphia (Children's Hospital of Philadelphia Foundation)
• Original Assignee: Children's Hospital of Philadelphia (Children's Hospital of Philadelphia Foundation), Trustees Of The University Of Pennsylvania (University of Pennsylvania)
• Inventors: Stoffers, Doris, De Leon, Diva D., Stanley, Charles
• Primary Examiner(s): Skowronek, Karlheinz R
• Assistant Examiner(s): NIEBAUER, RONALD T
• Application Number:
  US12/081,123
• Publication Number:
  US 20080269130A1
• Time in Patent Office: 3,288 Days
• Field of Search: None
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics

Abstract

This invention relates to methods of treating and ameliorating congenital and neonatal hyperinsulinism and post-prandial hypoglycemia, comprising the step of administering an antagonist of the Glucagon-Like Peptide-1 (GLP-1) receptor, e.g. a GLP-1 fragment or analog thereof.

Claims

1. A method of treating congenital hyperinsulinism in a subject having congenital hyperinsulinism associated with or due to a loss of function mutation in the K_ATP channel, the method comprising the step of administering to said subject an effective amount of a peptide, wherein the amino acid sequence of the peptide consists of the amino sequence set forth in SEQ ID NO:

1.

2. The method of claim 1, wherein said congenital hyperinsulinism is associated with a mutation in a gene encoding a sulfonylurea receptor (SUR-1).

3. The method of claim 1, wherein said congenital hyperinsulinism is associated with a mutation in a gene encoding a Kir6.2.

4. The method of claim 1, whereby administering is via intravenous, parenteral, oral, intraperitoneal, subcutaneous administration or a combination thereof.

5. The method of claim 1, wherein said peptide is administered subcutaneously.

6. The method of claim 1, wherein said peptide is administered intravenously.

7. The method of claim 1, wherein said peptide is administered by infusion.